23 C
Vientiane
Monday, April 28, 2025
spot_img
Home Blog Page 167

Sensodyne Tackles Widespread Tooth Sensitivity in Malaysia with Fresh Mint Launch and Nationwide “A Happy Mouth is… a Happy Mind” Campaign in conjunction with World Oral Health Day!

KUALA LUMPUR, Malaysia, April 10, 2025 /PRNewswire/ — A new survey* conducted by Haleon, a global leader in consumer health, reveals a significant public health concern in Malaysia: tooth sensitivity. The survey of 248 Malaysians showed that a staggering 69% experience regular tooth sensitivity, with 61.8% enduring the discomfort rather than seeking dental treatment. Sensodyne, Malaysia’s #1 sensitivity toothpaste brand*, is re-launching its Fresh Mint toothpaste with a new and improved formula that provides long-lasting relief and encourages Malaysians to stop enduring and start living life worry-free from sensitivity – because Why Tahan?

Sensodyne Tackles Widespread Tooth Sensitivity in Malaysia with Fresh Mint Launch and Nationwide "A Happy Mouth is… a Happy Mind" Campaign in conjunction with World Oral Health Day!
Sensodyne Tackles Widespread Tooth Sensitivity in Malaysia with Fresh Mint Launch and Nationwide “A Happy Mouth is… a Happy Mind” Campaign in conjunction with World Oral Health Day!

The survey, conducted among the 18-40 age-group, showed that younger generations are highly affected by this issue. A total of 38.4% of the respondents were aged 26-40, while 34.6% belonged to the 18–25 age category, indicating a need for an increased awareness and effective solutions for sensitive teeth across all age groups.

This common condition disrupts the everyday habits of most Malaysians, with cold foods (58.5%) being the leading cause of sensitivity, followed by sweets and hot drinks, based on the survey. These findings highlight how tooth sensitivity prevents individuals from fully enjoying everyday pleasures. Alarmingly, only 13.1% actively address sensitivity by brushing their teeth to relieve discomfort, reflecting low awareness of best practices.

In response to this widespread issue, Sensodyne has announced the launch of Sensodyne Fresh Mint. This new toothpaste, specially developed with an improved formula, provides lasting relief and allows Malaysians to live life without the fear of sensitivity. Sensodyne Fresh Mint offers a range of benefits to tackle sensitivity:

  • 24-Hour Protection: With continued use and twice daily brushing, enjoy your favourite foods and drinks throughout the day without irritation.
  • Lasting freshness: Sensodyne Fresh Mint with improved formulation provides lasting freshness with regular use.

Triple-Action Cleaning Technology: This innovative formula polishes teeth, removes surface stains, and brushes away bacteria for a cleaner, healthier smile.

Sensodyne’s effectiveness is further validated by a Real-World Evidence study published in the International Journal of Environmental Research and Public Health (IJERPH). The Dentine Hypersensitivity Experience Questionnaire (DHEQ) study identified that:

  • 100% of regular Sensodyne users expressed daily satisfaction.
  • 98% reported improvement in their sensitivity symptoms.

“Too many Malaysians endure the discomfort of tooth sensitivity, missing out on simple joys like a refreshing iced coffee or a scoop of ice cream. Instead of addressing the root cause, many wait for the pain to pass. These findings underscore the urgent need for effective solutions and greater awareness around sensitivity. That’s why Sensodyne, in collaboration with the Malaysian Dental Association, is intensifying efforts to raise awareness and promote early intervention – because if left untreated, sensitivity can lead to more serious dental issues,” shared Law Chen, Marketing Director at Haleon Malaysia, Singapore and Brunei.

Dr Mohd Salman bin Masri, a Periodontist representing Malaysian Dental Association (MDA) echoed this sentiment: “Tooth sensitivity is more than just a minor inconvenience – it can signal deeper oral health issues. Yet, many Malaysians endure it without realising how much it affects their daily lives. According to a real-life study recently published in the International Journal of Environmental Research and Public Health, 93% of respondents said sensitivity takes the joy out of eating and drinking, impacting both physical comfort and emotional well-being.  That’s why it’s crucial to address sensitivity early – right when you first feel it. Ignoring it could lead to bigger problems down the line.”

To commemorate World Oral Health Day, Sensodyne is launching a nationwide campaign “A Happy Mouth is…A Happy Mind” to unite Malaysians. As part of this initiative, Sensodyne is collaborating with the Malaysian Dental Association to offer one month of complimentary dental check-ups across more than 500 clinics in Malaysia from 21 April to 21 May 2025.

Sensodyne Fresh Mint is available nationwide at pharmacies, dental clinics, minimarkets, supermarkets, and hypermarkets and provision stores

To learn more about the campaign, visit www.sensodyne.com.my or follow Sensodyne Malaysia’s Facebook and Instagram accounts.

-Ends-

*“GlaxoSmithKline Consumer Healthcare Sdn. Bhd. calculation based in part on data reported by NIQ through its Retail Index Service for the Sensitive segment within the Toothpaste category for the 12 months period ending April 2023, for the Total Malaysia Market. (Copyright © 2023, NIQ.)”

Tadjoedin et al. A Real-World Study on the Quality of Life of Consumers with Dentine Hypersensitivity and the Benefits of Hypersensitivity Toothpaste Use. Int. J. Environ. Res. Public Health 2025, 22, 175. https://doi.org/10.3390/ijerph22020175 

About Haleon

Haleon (LSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories – Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands – such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, Parodontax and Centrum – are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com   

About Haleon Malaysia

Haleon (LSE: HLN) is a global leader in consumer health, with brands trusted by millions of consumers globally. Haleon Malaysia employs over 500 people whose purpose is to deliver better everyday health with humanity. With market leading positions in oral care, pain relief, and wellness, we work closely with pharmacists, physicians, and retailers to increase awareness of everyday health issues and concerns and emphasise the importance of self-care. Haleon’s Hulu Kelang site in Kuala Lumpur also supplies countries around the world with high quality and innovative consumer healthcare products, such as Panadol, ENO and Polident.

 

Hyundai Mobis Seeks Open Innovation Opportunities for Mobility in Detroit

  • Hyundai Mobis held Mobis Mobility Day in Detroit … introducing its business vision and investment status under the theme of “Mobis in Global.”
  • Exploring local collaboration and business opportunities in Detroit, which is home to big 3 automaker and recently emerging as a key hub for mobility startups.
  • It is expanding the discovery of outstanding startups and strategic investment performance … strengthening support for business proofs of concept, led by MVSV, its US-based investment subsidiary.

SEOUL, South Korea, April 10, 2025 /PRNewswire/ — Hyundai Mobis (KRX 012330) held an investment presentation for startups in North America, setting out to secure a future mobility technology alliance. The company announced on 10 that it held the 4th annual Mobis Mobility Day in Detroit, home to the automotive industry. The event had originally been held in Silicon Valley every year. Mobis Mobility Day is an event where Hyundai Mobis introduces its business vision and investment status to global startups, academia, and investors.

Based on its automobile manufacturing infrastructure, Detroit is emerging as a hub for a large number of mobility startups armed with AI and software, as well as production and quality control capabilities.

In this event, these regional characteristics led to many presentations by promising local startups Hyundai Mobis invited. It is reported that in-depth discussions were made regarding mobility trends, particularly in the fields of robotics and cleantech.

Hyundai Mobis changed the venue from Silicon Valley to Detroit this year, considering that its recent global orders have been concentrated on North American customers. The company also considered that by expanding investment and cooperation with promising local startups and jointly developing superior technologies with them, it would be able to promote its products to customers more easily in the future.

During the event, Hyundai Mobis introduced its latest innovations in software-defined vehicle (SDV), electrification, and automotive electronics under the theme of “Mobis in Global,” with presentations on its business vision, open innovation achievements, and investment strategies. It is reported that the event was a great success, attracting over 200 local customer and startup officials. Presentations were given by employees of Mobis Technical Center of America, providing an engaging and informative experience.

“It is becoming important to discover outstanding global startups and make strategic investments to secure innovative technologies that will lead the paradigm shift in mobility,” said Mitchell Yun, investment manager at Mobis Ventures Silicon Valley (MVSV), the organizer of the event. “This year, we will expand our support for business proofs of concept (PoCs), including technology and business feasibility reviews, and strengthen our collaboration to preempt the market.” 

Hyundai Mobis launched Mobis Ventures Silicon Valley, its open innovation base, in Silicon Valley in 2018, and the cumulative amount of money it has invested in startups exceeded 200 billion won last year. Last year, the company made a new investment of 15 million dollars in the US semiconductor company Elevation Microsystems, and in 2020, it invested in the UK’s Envisics and is currently collaborating with it on augmented reality-based head-up display (AR-HUD) technology. It also continues to cooperate with promising companies in the core technology fields of future mobility, including Zendar, a developer of high-performance image radars for autonomous driving, LightIC, an AI-based semiconductor-type lidar company, and Sonatus, a software platform company.

About Hyundai Mobis

Hyundai Mobis is the global no. 6 automotive supplier, headquartered in Seoul, Korea. Hyundai Mobis has outstanding expertise in sensors, sensor fusion in ECUs and software development for safety control. The company’s products also include various components for electrification, brakes, chassis and suspension, steering, airbags, lighting, and automotive electronics. Hyundai Mobis operates its R&D headquarters in Korea, with four technology centers in the United States, Germany, China, and India. For more information, please visit the website at http://www.mobis.com.

Media Contact 
Choon Kee Hwang: ckhwang@mobis.com
Jihyun Han: jihyun.han@mobis.com

 

Standard Chartered and OKX launch world-leading collateral mirroring programme

  • In collaboration with Franklin Templeton, the programme will enable crypto and tokenised money market funds as collateral.
  • The programme will see leading institutions, such as Brevan Howard Digital, onboard onto this pioneering programme.

DUBAI, UAE, April 10, 2025 /PRNewswire/ — Standard Chartered and OKX, a leading cryptocurrency exchange and global onchain technology company, today announced the launch of a ground-breaking, world-leading collateral mirroring programme, enabling institutional clients to utilise cryptocurrencies and tokenised money market funds as off-exchange collateral for trading. This initiative significantly enhances security and capital efficiency for institutional clients by using a Globally Systemically Important Bank (G-SIB) as the custodian for their collateral.

Margaret Harwood-Jones, Global Head of Financing and Securities Services at Standard Chartered said: “We understand the critical importance of robust and secure custody solutions, especially in the evolving digital asset landscape, and our collaboration with OKX to enable the use of cryptocurrencies and tokenised money market funds as collateral represents a significant step forward in providing institutional clients with the confidence and efficiency they need. By leveraging our established custody infrastructure, we are ensuring the highest standards of security and regulatory compliance, fostering greater trust in the digital asset ecosystem.”

The collateral mirroring capability has been launched as a Pilot within the Dubai Virtual Asset Regulatory Authority’s (VARA) regulatory framework, and it allows clients to benefit from enhanced protection against counterparty risk, a significant concern in the current digital asset markets. Standard Chartered acts as the independent, regulated custodian in the Dubai International Financial Centre (DIFC), regulated by the Dubai Financial Services Authority, ensuring the safe storage of the assets used as collateral, while OKX, through its VARA regulated entity, manages collateral and facilitates transactions. Franklin Templeton will be the first in a series of money market funds that will be offered under the OKX-SCB programme.

Hong Fang, President of OKX, said: “As the digital assets ecosystem becomes more ingrained within traditional finance, we strive to both drive growth and safeguard client assets in the most capital efficient manner. By leveraging Standard Chartered’s position as a top custodian globally, as well as OKX’s market leadership in cryptocurrency trading, the partnership sets an industry standard for current and potential institutional clients to deploy trading capital at scale in a trusted environment.”

Franklin Templeton, a recognised leader in tokenisation and real world assets (RWA), continues to innovate by leveraging blockchain technology to deliver cutting-edge solutions to customers and clients. Through this collaboration, OKX clients will gain access to on-chain assets developed by Franklin Templeton’s Digital Assets Team, seamlessly integrating them into their financial and operational structures.  

Roger Bayston, Franklin Templeton Head of Digital Assets, says “Leveraging blockchain technology, our platform is built to support the dynamic and ever-evolving  financial ecosystem. We take an authentic approach, from directly investing in blockchain assets to developing innovative solutions with our in-house team. By ensuring assets are minted on-chain, we enable true ownership, allowing them to move and settle at blockchain speed – eliminating the need for traditional infrastructure.”

Brevan Howard Digital, the dedicated crypto and digital asset division of Brevan Howard, a leading global alternative investment manager, is among the first few institutions to onboard onto this pioneering programme, highlighting the importance of such capabilities being offered by a leading international cross-border bank and a highly reputable global exchange.

Ryan Taylor, Group Head of Compliance at Brevan Howard and CAO of Brevan Howard Digital, commented: “This programme is the latest example of the continued innovation and institutionalisation of the industry. As a significant investor in the digital assets space, we are thrilled to partner with industry leaders to further grow and evolve the crypto ecosystem globally.”

Previous press releases:

Sep 2024: Standard Chartered launches digital asset custody service in the UAE

Oct 2024: OKX names Standard Chartered as institutional third-party custody partner | Standard Chartered

About OKX

OKX is a leading global crypto exchange. Trusted by more than 60 million global users, OKX is known for being one of the fastest and most reliable crypto apps in the world.

As a top brand partner of English Premier League champions Manchester City FC, McLaren Formula 1 and Olympian Scotty James, OKX aims to supercharge the fan experience with new engagement opportunities. OKX is also the top partner of the Tribeca Festival as part of an initiative to bring more creators into web3.

OKX is committed to transparency and security and publishes its Proof of Reserves on a monthly basis. To learn more about OKX, download our app or visit: okx.com.

Disclaimer

About Brevan Howard Digital

Brevan Howard Digital (“BH Digital”) is the dedicated crypto and digital asset division of Brevan Howard, providing institutional investors access to the wide range of diverse opportunities presented by the structural disruption and innovation of blockchain technology. BH Digital offers unconstrained, alpha-centric, and diversified exposure to investment opportunities across the digital asset ecosystem via a multi-manager, multi-strategy approach across both private and public markets. The 60+ member team manages more than $2bn and operates in 8 offices worldwide. For more information, visit www.brevanhoward.com/brevanhoward-digital/.

About Standard Chartered

We are a leading international banking group, with a presence in 53 of the world’s most dynamic markets. Our purpose is to drive commerce and prosperity through our unique diversity, and our heritage and values are expressed in our brand promise, here for good.

Standard Chartered PLC is listed on the London and Hong Kong stock exchanges.

For more stories and expert opinions please visit Insights at sc.com. Follow Standard Chartered on X, LinkedIn, Instagram and Facebook.

About Franklin Templeton 

Franklin Resources, Inc. [NYSE:BEN] is a global investment management organization with subsidiaries operating as Franklin Templeton and serving clients in over 150 countries. Franklin Templeton’s mission is to help clients achieve better outcomes through investment management expertise, wealth management and technology solutions. Through its specialist investment managers, the company offers specialization on a global scale, bringing extensive capabilities in fixed income, equity, alternatives and multi-asset solutions. With more than 1,500 investment professionals, and offices in major financial markets around the world, the California-based company has over 75 years of investment experience and $1.58 trillion in assets under management as of February 28, 2025. For more information, please visit franklintempleton.com and follow us on LinkedIn, X and Facebook

All investments, including money funds, involve risk, including loss of principal. There are risks associated with the issuance, redemption, transfer, custody, and record keeping of shares maintained and recorded primarily on a blockchain. For example, shares that are issued using blockchain technology would be subject to risks, including the following: blockchain is a rapidly-evolving regulatory landscape, which might result in security, privacy or other regulatory concerns that could require changes to the way transactions in the shares are recorded.

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ — Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa Therapeutics Inc. (Nasdaq: ATOS). The collaboration leverages Nona’s proprietary H2L2 Harbour Mice® platform to identify next-generation therapeutic candidates for breast cancer.

Nona Biosciences’ proprietary Harbour Mice® platform employs transgenic mice to generate fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization. Combined with the single B cell cloning technology, this platform offers a powerful approach to developing therapeutic antibodies and accelerating drug discovery and development. To date, Harbour Mice® platform has been applied in more than 250 drug discovery programs across multiple therapeutic areas and has been widely recognized by global partners.

“We are pleased to collaborate with Atossa Therapeutics to discover next-generation antibody therapies for breast cancer,” said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences. “This partnership highlights the value of our proprietary Harbour Mice® platform and reflects the industry’s growing demand for innovative antibody discovery solutions. With Nona’s industry-leading technology and expertise, we look forward to supporting Atossa’s exploration of antibody-based approaches within their oncology pipeline.” 

About Nona Biosciences

Nona Biosciences is a global biotechnology company committed to cutting-edge technology innovations and providing a total solution from “Idea to IND” (“I to ITM“), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team.

Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain-only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: www.nonabio.com.

 

Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China’s first hemophilia B gene therapy, was officially approved

SHANGHAI, April 10, 2025 /PRNewswire/ — Belief BioMed (“BBM”) and Takeda China today jointly announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with moderate to severe hemophilia B (congenital coagulation factor IX deficiency). As the first approved hemophilia B gene therapy in China1, BBM-H901 is developed and manufactured by BBM, and Takeda China is responsible for its commercialization in mainland China, Hong Kong and Macau. The two parties will integrate their respective resource advantages to accelerate the provision of this breakthrough gene therapy to patients and jointly open up a new landscape in the field of hemophilia B treatment.

Dr. Xiao Xiao, Co-founder, Chairman and Chief Science Officer of BBM, said: “BBM has always been committed to R&D and innovation in the field of cutting-edge gene therapy, and is dedicated to filling unmet medical needs. The approval of BBM-H901 is an important milestone in the development of BBM. As the first hemophilia B gene therapy drug independently developed in China1, BBM-H901 will provide a new treatment option for hemophilia B patients, which is expected to provide patients with an innovative treatment solution and help them return to a normal life. BBM will work together with Takeda China to accelerate the rapid implementation of this innovative therapy. In the future, BBM will strive to accelerate the overseas commercialization process of BBM-H901, hoping to benefit more hemophilia B patients. “

Sean Shan, Senior Vice President of Takeda Pharmaceutical and President of Takeda China, said: “Takeda is honored to collaborate with BBM to bring the first locally developed hemophilia B gene therapy1 to the Chinese patients with hemophilia B. The approval of BBM-H901 will further enrich our portfolio in hemophilia and rare disease areas, and will help more patients to benefit from innovative treatments. In the future, Takeda China will continue to deepen our strategic cooperation with local partners, to accelerate the commercialization of more breakthrough therapies, ensure China’s medical innovation can benefit more patients and contribute to the high-quality development of China’s rare disease industry.”

Hemophilia B is an inherited bleeding disorder caused by the deficiency of factor IX (FIX)2. For a long time, patients can only rely on prothrombin complex concentrate (PCC) or FIX as a replacement therapy3,4. Persistent and frequent bleeding can easily lead to damage of joint structure and function, resulting in a high disability rate5. This not only brings great physical pain and inconvenience to patients, but also comes with the risk of infection, blood clots, etc.3,4. The high medical treatment costs also bring a heavy and constant economic burden on the patient’s family.

BBM-H901, based on a recombinant adeno-associated virus (rAAV) vector, can deliver the optimized human coagulation FIX gene into liver cells of patients. Then, coagulation FIX is continuously expressed and secreted into the bloodstream using the host cell gene transcription system, thereby promoting coagulation.  

Professor Zhang Lei from the Blood Disease Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), leading investigator of the registered clinical study of BBM-H901, said: “The traditional treatment of hemophilia B requires frequent intravenous injections, and the factor level fluctuates with the half-life of exogenous coagulation factors. Some patients are also at risk of developing inhibitors, leading to reduced treatment effectiveness. The approval of BBM-H901 has brought revolutionary hope to Chinese patients with hemophilia B. By a single dosing, the risk of bleeding and joint damage can be reduced, and patients are back to a normal life. We believe that with the continuous breakthrough of scientific research and the accumulation of clinical experiences, the treatment of hemophilia will enter a new era and patients will enjoy a higher quality of life.”

In 2019, the first Investigator-initiated Trial (IIT) of BBM-H901 was launched. In 2022, the research results of IIT were successively published on international authoritative journals, The Lancet-Hematology and The New England Journal of Medicine5,6. Ten adult patients with moderate to severe hemophilia B were included in the study, with a median follow-up of 58 weeks after gene therapy, achieving a mean FIX activity of 36.9 IU/dL (one Stage Assay actin FSL aPTT reagent). There were no serious adverse events (SAEs) during the follow-up process, and there were no grade 3-4 adverse events (AEs)5.  The long-term follow-up results of more than 3 years were orally presented at the 2024 International Society on Thrombosis and Haemostasis (ISTH) Congress. Compared with the published data in 2022, the patient’s FIX activity remained stable at all follow-up nodes. No drug-related SAEs, thrombotic events, nor inhibitors were observed8.

In August 2021, the Investigational New Drug (IND) application of BBM-H901 was approved in China. In August 2022, BBM-H901 obtained the Breakthrough Therapy Designation by the Center for Drug Evaluation, the National Medical Products Administration7, and later on Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA). In 2024, BBM-H901 obtained the Rare Pediatric Disease Designation (RPDD) from the FDA and the Advanced Therapy Medical Products (ATMP) from the European Medicines Agency (EMA).

In December 2024, BBM released the results of the Phase III clinical study at the 66th Annual Meeting of the American Society of Hematology (ASH). The results showed that after 52 weeks of follow-up, the mean annualized bleeding rate (ABR) of the participants was 0.6, the average FIX activity reached 55.08 IU/dL (one Stage Assay SynthaSIL aPTT reagent), and the average number of infusions of FIX drug decreased from 58.2 times/year before gene therapy treatment to 2.9 times/year after that. Twenty-one of the 26 participants (80.8%) had no bleeding events after treatment, and all participants had no SAEs8. The study is still in the process of continuous follow-up.

###

About Belief BioMed

Belief BioMed Inc. (BBM) is a global biotech company that integrates the research and development (R&D), manufacturing and clinical application of gene therapy products. The company is committed to providing innovative and more effective gene therapies for severe genetic and chronic diseases through safe and efficient viral vector technology. BBM has developed hundreds of key vector technologies, including HEK293 cell suspension serum-free culture process and full-scale chromatography purification process, and has established a commercial production platform for gene therapy drugs. The company has been building up its capabilities in a variety of fields including novel AAV capsids targeting different tissues, efficient transgene expression cassette design, and advanced clinically applicable vector manufacturing process. It has also established an extensive R&D pipeline covering a wide range of unmet clinical needs in different therapeutic areas such as hemophilia, DMD, Parkinson’s disease, osteoarthritis, etc. Several product pipelines have entered clinical studies or submitted Investigational New Drug (IND). The Biologics License Application (BLA) of a gene therapy for the treatment of adult patients with hemophilia B, has been approved by the NMPA of China. For more information, visit www.beliefbiomed.com.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

[1] Up to April 2025. https://www.nmpa.gov.cn/yaopin/index.html

[2] Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association / Hemophilia Treatment Center Collaborative Network of China. Chinese guidelines on the treatment of hemophilia (version 2020). Chin J Hematol..2020;41(4):265-271

[3] Mortensen GL,et al. Haemophilia. 2018;862–872

[4] Srivastava A, et al. Haemophilia. 2020;001–158.P95

[5] Xue F, et al. Lancet Haematol. 2022 Jul;9(7):e504-e513

[6] Xue F, et al. N Engl J Med. 2022 Oct 27;387(17):1622-1624

[7] https://www.cde.org.cn/main/xxgk/listpage/da6efd086c099b7fc949121166f0130c

[8] Feng X,et al. 2024 ASH. Poster 3582

 

 

UnionPay International Powers Seamless Payments for a Culturally and Technologically Enriching Japan Travel Experience

SHANGHAI, April 10, 2025 /PRNewswire/ — April brings one of Japan’s most anticipated international showcases of cutting-edge technology and innovation, drawing visitors from around the world. With an increasingly diverse tourism offering, Japan is reaffirming its status as a top global travel destination. In response to rising demand, UnionPay International is expanding its acceptance network and payment capabilities across Japan, offering global travelers a secure and convenient way to experience the country at its best.

This growing demand is evident in Japan’s record-breaking tourism numbers. In February 2025, the country welcomed approximately 3.26 million international visitors, up 16.9% year-over-year, setting a new record. South Korea led the inbound market, followed by China. In 2024, international travelers spent a total of ¥8.14 trillion in Japan, with the largest shares going to accommodation (¥2.74 trillion), shopping (¥2.4 trillion), and dining (¥1.2 trillion). These figures underscore the significant economic contribution of inbound tourism and highlight the growing need for seamless, efficient payment solutions.

UnionPay International is meeting this demand by enhancing its payment services across Japan. From the bustling streets of Tokyo to the serene landscapes of Hokkaido, UnionPay International allows travelers to focus on discovery and enjoyment—without the hassle of payment concerns.

Since launching operations in Japan in 2005, UnionPay International has partnered with 15 major local acquirers to establish a robust acceptance network. Today, UnionPay cards are accepted at 82% of merchants and 100% of ATMs nationwide. Travelers also have access to more than 300,000 contactless terminals and 1.5 million QR code payment terminals.

UnionPay International’s services are designed to support every stage of the journey. Travelers can book flights on over 90 international airlines, reserve hotels on major platforms, and shop in-store at key retailers.

Tax refunds are just as accessible—shoppers spending over 5,000 yen at tax-free stores can easily receive their rebates directly to their UnionPay cards.

Innovating Payment Interconnectivity Worldwide

As a global financial infrastructure provider and leading international card network, UnionPay International is dedicated to improving cross-border payment connectivity. Outside the Chinese Mainland,over 260 million UnionPay cards have been issued in 83 countries and regions; in 37 markets, more than 220 UnionPay-powered e-wallets offer broad access to mobile payments.

This global expansion makes it easier for international tourists—including those from key source markets such as Hong Kong, Macau SAR, South Korea, Southeast Asia, Australia, and Europe—to use payment tools they already trust while traveling in Japan.

UnionPay International is the top card brand in the Greater Bay Area by issuance and coverage. In Africa, UnionPay cards are accepted in 51 countries, with 13 markets issuing over 5 million cards. In SEA, nearly 50 million UnionPay cards have been issued, supported by more than 30 e-wallets in the region. In Europe, Spanish provider Pecunpay has launched UnionPay cards, and French users can now apply for UnionPay cards via the “Yi An” app.

UnionPay International’s ongoing investment in Japan’s payment infrastructure reflects a shared commitment to openness, innovation, and cultural connection. This vision is aligned with the themes of this season’s major international event, where tradition meets technology and culture embraces the future.

From shopping in department stores to navigating Japan’s extensive transit system, UnionPay International empowers travelers to explore more, worry less, and fully immerse themselves in Japan’s unique charm and forward-thinking spirit.

RoboUP 2025 Product Launch: More Than You See – A Smarter, User-Driven Mowing Experience

SHENZHEN, China, April 10, 2025 /PRNewswire/ — As a leading innovator in robotic lawn care solutions, RoboUP announces the launch of the latest smart boundary wire-free robot mower, the TM01 Series 2025, under the theme More Than You See, highlighting innovation beyond what meets the eye. Building on the success of the T1200 Pro & T600, it addresses key pain points like missed edges, remapping hassles, and uneven cuts, ensuring a seamless mowing experience. Join the online launch event for a chance to win a free robot mower, exciting prizes, and expert insights.

Addressing Key Pain Points with Game-Changing Solutions

While boundary wire-free robot mowers have advanced remarkably, certain aspects still have room for improvement. The TM01 Series 2025 is engineered to overcome these obstacles, offering exceptional efficiency and convenience.

All the feedback from the market and users inspires RoboUP to improve and refine the new products. Join the live stream to see these innovations in action and learn how TM01 Series 2025 is transforming lawn care with smarter automation and user-driven technology.

Launch Event Highlights: An Interactive Experience You Can’t Miss

The TM01 Series 2025 launch event offers an exclusive first look at the future of robotic lawn care.

  • Expert Insights: Industry leaders will break down how the TM01 Series 2025 is reshaping convenience, efficiency, and performance in the world of smart lawn care.
  • Real User Stories: Hear firsthand experiences from actual users. Know what surprised them, what they love, and how the TM01 has transformed their lawn care routine.
  • Smart Mowing Masterclass: Learn how to optimize mowing schedules, adapt to different gardens, and get the most out of your boundary wire-free robot mower in this expert-led session.
  • Local Services & Support: Discover RoboUP’s expanding global service network, ensuring hands-on support and a seamless ownership experience wherever you are.

Exclusive Prizes Just for You
To mark this exciting launch, RoboUP is hosting an interactive social media event featuring exclusive giveaways and special awards. The lucky winner will receive an iPhone 16 and a T1200 Pro 2025 during the RoboUP launch event on April 17th. Don’t miss the biggest launch discount. Subscribe now for a chance to win a free RoboUP T1200 Pro robot mower and access exclusive promotions.

About RoboUP
RoboUP emerged from the vision of creating the ideal living environment, harmonizing with nature and homeowners. The journey began in 2016, and by 2022, RoboUP had set the bar high in the world of service robots. With a mission to transform the way people interact with their gardens, RoboUP helps users create the living space they deserve. Guided by ‘Thoughtful Robotics’, RoboUP develops robot mowers that simplify everyday lawn care, giving homeowners more time to enjoy what truly matters.

 

Montran Wins Central Banking Award for Payment Services Development

NEW YORK, April 10, 2025 /PRNewswire/ — Montran has been honored with the ‘Payment Services Development’ award at the Central Banking Awards. This prestigious recognition underscores Montran’s commitment to achieving financial infrastructure interoperability through our Instant Payments System (IPS).

The deployment of the Montran IPS in various regions around the world has been instrumental in empowering central banks, clearinghouses, commercial banks, NBFIs, MNOs, merchants, agents and end-users with a cutting-edge interoperable instant payment solution.

With ten live instant payment systems (IPS) deployed across the globe—from Angola to Panama—Montran continues to empower financial ecosystems with innovative solutions that enhance transaction speed, security, and accessibility. The recent go-live of BORICA’s TIPS Connectivity Module in Bulgaria further demonstrates Montran’s commitment to advancing cross-border instant payments, ensuring operational efficiency and compliance with European standards.

Driving Instant Payments Forward

Montran’s IPS platform has been designed for scalability, flexibility, and security, making it the preferred choice for central banks and national clearing systems. Built to support 24/7 real-time processing, the system offers:

  • Advanced fraud management to safeguard transactions
  • Seamless QR code-based payments for instant digital transactions
  • 5,000+ transactions per second processing capacity
  • Direct integration with international systems, including ECB TIPS and PAPSS

Since the launch of its first IPS production system in 2018, Montran has continuously enhanced its platform with proxy alias modules, advanced liquidity management, and configurable fraud detection tools—ensuring a future-proof payment infrastructure.

 “As instant payments become the global standard, we remain committed to helping central banks and financial institutions accelerate digital transformation with scalable, reliable financial infrastructure,” said Cristi Jurca, IPS Product Owner at Montran.

Global Expansion & Future Innovations

Montran’s instant payments ecosystem is growing rapidly, with three additional systems currently in progress and major initiatives underway in Guatemala and Asia. The company is also focused on integrating IPS with emerging financial technologies, including Central Bank Digital Currencies (CBDCs) and enhanced fraud risk management solutions.

“The evolution of digital payments is accelerating, and Montran is leading the way by providing robust, real-time financial solutions that drive economic growth and financial inclusion,” said Ciprian Tesa, Chief Technology Officer at Montran.

Montran remains committed to its purpose to unify the world financially by equipping central banks, financial institutions, and payment service providers with next-generation digital payment technology. 

About Montran

Montran is the leading provider of Payment and Capital Market Infrastructure solutions, servicing the world’s foremost financial institutions with mission critical installations and operations in over 90 countries. Discover more at www.montran.com.